Profile data is unavailable for this security.
About the company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
- Revenue in USD (TTM)689.00k
- Net income in USD-43.01m
- Incorporated2009
- Employees31.00
- LocationCardiff Oncology Inc11055 Flintkote AveSAN DIEGO 92121-1220United StatesUSA
- Phone+1 (858) 952-7570
- Fax+1 (858) 217-4768
- Websitehttps://cardiffoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outlook Therapeutics Inc | 0.00 | -94.05m | 121.35m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Ventyx Biosciences Inc | 0.00 | -152.52m | 122.33m | 75.00 | -- | 0.4386 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
Vigil Neuroscience Inc | 0.00 | -82.60m | 122.64m | 66.00 | -- | 1.34 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Cidara Therapeutics Inc | 18.86m | -123.53m | 122.96m | 69.00 | -- | 1.06 | -- | 6.52 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Seres Therapeutics Inc | 64.00k | -165.29m | 124.55m | 233.00 | -- | 5.21 | -- | 1,946.13 | -1.14 | -0.2271 | 0.0004 | 0.1405 | 0.0002 | -- | -- | 274.68 | -60.50 | -41.51 | -82.15 | -54.13 | -- | -- | -258,259.40 | -170.14 | -- | -20.45 | 0.00 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Pyxis Oncology Inc | 16.15m | -57.36m | 124.88m | 54.00 | -- | 0.8124 | -- | 7.73 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
Repare Therapeutics Inc | 66.52m | -84.05m | 126.26m | 179.00 | -- | 0.7216 | -- | 1.90 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Skye Bioscience Inc | 0.00 | -21.24m | 126.51m | 11.00 | -- | 1.67 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Cardiff Oncology Inc | 689.00k | -43.01m | 127.83m | 31.00 | -- | 2.47 | -- | 185.54 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 129.48m | 36.00 | -- | -- | -- | 2.62 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
TriSalus Life Sciences Inc | 26.89m | -58.65m | 129.85m | 112.00 | -- | -- | -- | 4.83 | -1.68 | -1.68 | 0.8963 | -0.6706 | 0.8812 | 1.23 | 6.75 | 240,098.20 | -181.70 | -- | -265.24 | -- | 87.10 | -- | -206.19 | -- | 2.00 | -26.43 | 17.43 | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -52.20m | 132.67m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Sep 2024 | 2.52m | 5.42% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 2.12m | 4.56% |
Geode Capital Management LLCas of 30 Sep 2024 | 928.23k | 1.99% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 832.65k | 1.79% |
MAI Capital Management LLCas of 30 Sep 2024 | 663.36k | 1.43% |
Renaissance Technologies LLCas of 30 Sep 2024 | 602.38k | 1.29% |
Morgan Stanley & Co. LLCas of 30 Sep 2024 | 426.35k | 0.92% |
Two Sigma Advisers LPas of 30 Sep 2024 | 331.20k | 0.71% |
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 309.60k | 0.67% |
TIAA-CREF Investment Management LLCas of 30 Sep 2024 | 284.65k | 0.61% |